Previous 10 | Next 10 |
2023-10-18 07:45:24 ET More on Intellia, Regeneron, etc. Intellia Therapeutics: Massive OpEx Begin To Weigh On HAE Prospects Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 21st Annual Global He...
NTLA-2001 is the first-ever investigational in vivo CRISPR-based gene editing therapy cleared to enter late-stage clinical development CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company f...
2023-10-13 18:11:38 ET Summary We rate Alnylam Pharmaceuticals, Inc.'s common stock a Buy on the dip after the complete response letter, CRL for Patisiran. The investment thesis is based on the high probability of success for Vutrisiran, the company's next-generation inverse RNA o...
2023-10-13 09:12:27 ET More on Intellia Therapeutics Intellia Therapeutics: Massive OpEx Begin To Weigh On HAE Prospects Regeneron and Intellia expand gene editing partnership Seeking Alpha’s Quant Rating on Intellia Therapeutics For further details se...
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that the European Medicines Agency (EMA) has...
2023-10-12 08:57:00 ET Over the course of 2007 to 2021, growth stocks dramatically outperformed value stocks. Historically low interest rates, coupled with the emergence of the knowledge economy, sparked one of the longest bull markets in growth stocks in history. Nonetheless, value sto...
2023-10-10 18:08:45 ET Summary Despite a positive panel recommendation, the FDA rejected the Alnylam Pharmaceuticals, Inc. application to market Onpattro for ATTR-CM, citing a lack of meaningful evidence of clinical efficacy. Amvuttra has always been the bigger opportunity in ATTR...
2023-10-10 14:00:00 ET Intellia Therapeutics (NASDAQ: NTLA) has announced a good deal of positive news in recent months, from progress in clinical trials to an expanded partnership with big biotech Regeneron Pharmaceuticals . The gene editing company doesn't yet have a product o...
2023-10-10 10:07:00 ET Gene-editing specialist Intellia Therapeutics (NASDAQ: NTLA) has caught the attention of Cathie Wood. The founder and CEO of Ark Invest, an investment management firm focused on investing in innovative companies, includes Intellia as a top 10 holding in one of...
2023-10-03 10:07:00 ET Wall Street analysts are quite bullish right now on gene-editing specialist Intellia Therapeutics (NASDAQ: NTLA) -- expecting, on average, the stock to soar 167% in the coming 12 months. Yet, Intellia has a very long way to go before it has a chance to commerc...
News, Short Squeeze, Breakout and More Instantly...
Intellia Therapeutics Inc. Company Name:
NTLA Stock Symbol:
NASDAQ Market:
Intellia Therapeutics Inc. Website:
CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that it awarded inducement grants on July 22, 2024 to its Executive Vice Pr...
2024-07-23 12:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...